fashion -WSS

fashion

author：hotspot 2025-09-30 18:59:15 - browse：3955

Adam's take main illustration — Molly Ferguson/STAT

Anavex Life Sciences is in a tough spot. The serial dissembler of clinical trial results might be forced, finally, to tell the truth when it reads out its next study in Rett syndrome.

What sets Anavex apart from all the other biotechs on my radar screen is its habit of shifting the goalposts on clinical trials. Twice last year, first in February and then in December, Anavex announced “positive” outcomes from studies of its drug called blarcamesine — except the results were derived from efficacy endpoints that were not part of the original study designs.

If blarcamesine fails to achieve the pre-determined goals of clinical trials, the thinking apparently goes, then just make a post-hoc change to the study goals.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： FTC sues over Novant Health acquisition of two N.C. hospitals

Wikipedia

WSS

Senate committee scrutinizes Medicare Advantage brokers

UnitedHealth’s board chair also owns a personal investment firm

White House pharmacy plagued with problems, investigation finds

FDA struggles to regulate food additives, sometimes for decades

Will Ozempic

Senate committee scrutinizes Medicare Advantage brokers

explore

fashion

hotspot

Medical leaders decry Supreme Court decision on affirmative action

Hospital price transparency does save money, advocate argues

As demand for Covid shots wanes, Moderna seeks its next success

Biogen walks away from Aduhelm, years after polarizing approval

Apple is now the first public company to be valued at $3 trillion

First Opinion Podcast: Long Covid needs a new approach

What does generative AI mean for health care? We asked experts

STAT Summit: Biotech founders on deal

Wildfire smoke exposes gaps in outdoor worker protections

Medicare Advantage insurers face 0.2% cut to 2025 payments

knowledge

The Affordable Care Act has saved billions in health care costs

Humana’s losses in Medicare Advantage tank its stock

White House pharmacy plagued with problems, investigation finds

How climate

Philips to halt sales of sleep apnea machines in U.S.

Will Ozempic

leisure time

focus

Wikipedia

knowledge